News | Cath Lab | November 10, 2021

Philips Announces New Innovations and Clinical Data Supporting the Treatment of Patients with Cardiovascular Disease

Philips debuts three new solutions in the North American market to drive procedural innovation and workflow efficiency

#TCT2021 - Philips Image Guided Therapy System – Azurion

November 10, 2021 — Philips Healthcare announced North American availability of new innovations in its portfolio of cardiology solutions designed to seamlessly work together, strengthen clinical confidence, build efficiency throughout the care pathway, and improve cardiac care outcomes and experiences. The new updates, aimed at innovating and advancing procedures including percutaneous coronary intervention (PCI) to treat the narrowing of coronary arteries, are being announced at the Transcatheter Cardiovascular Therapeutics (TCT) 2021 meeting. In addition, Philips is putting a spotlight on new clinical data being presented at TCT that shows how novel minimally-invasive techniques are helping to innovate interventional procedures and improve patient outcomes.

 

The demands on cardiology departments are higher than ever before, forcing clinicians to balance the delivery of high-quality care for a growing volume of complex patients with the challenge of improving departmental efficiency at the same time. 

“Interventional physicians seek ever-more precise, accurate and efficient tools to decide, guide, treat and confirm the right therapy for the right patient at the point of care,” said Chris Landon, senior vice president and general manager, image guided therapy at Philips. “At this year’s TCT, we’re showing how we are continuously innovating and expanding our integrated ecosystem of interventional imaging systems and diagnostic and therapeutic devices to provide clinicians with a complete solution, from diagnosis to treatment and therapy monitoring, to optimize their workflow and the treatment of each individual patient.”

North America debut of Philips’ mobile interventional applications platform

The new Philips Interventional Applications Platform – IntraSight Mobile – is now available in North America. IntraSight Mobile brings together imaging and physiology applications on a mobile system for coronary and peripheral artery disease therapy. The IntraSight platform allows interventional cardiologists to perform intravascular ultrasound (IVUS) imaging and physiologic measurements of fractional flow reserve (FFR) and instant wave-free ratio (iFR) to accurately identify the location of lesions causing ischemia.

IntraSight Mobile builds on the success of Philips Interventional Applications Platform — IntraSight — a solution that integrates intravascular diagnostic applications into a smart, simple and seamless workflow solution for interventional labs. IntraSight Mobile is compatible with Philips’ current and future portfolio of imaging and physiology modalities. The system includes a touchscreen panel PC and a ruggedized, multi-modality touchscreen module mounted on a modern and easy to maneuver mobile cart for all environments. IntraSight Mobile offers clinicians an intuitive user interface and simplified workflow, enhancing the user experience while optimizing lab performance. Clinicians can customize the platform and select best-in-class tools that are right for their coronary or peripheral vascular patients.


Superior deliverability with new scoring balloon

The newly designed Philips Scoring Balloon Catheter RX – AngioSculpt Evo – has superior deliverability and the power to safely dilate resistant lesions. It comes with a combination of changes, including a smaller tip for smoother lesion entry, a hydrophilic coating to reduce friction, and a laser-cut hypotube for enhanced flexibility. The helical nitinol scoring elements wrap the balloon around its circumference to minimize slippage and lock to the lesion, delivering up to 25 times the force of a non-compliant balloon. This device is available for treatment of coronary artery stenosis, including in-stent restenosis.

Introduction of new laser system

The new Philips Laser System—Nexcimer—offers plug-and-play simplicity for coronary and peripheral atherectomy and lead extraction procedures. Smaller, lighter, and more maneuverable than the previous generation, the system starts up within 30 seconds, uses standard medical-grade 100-240V outlets, and has an intuitive touchscreen interface with guided workflow prompts that help lessen the need for technician training. It is the only system compatible with catheters with Level I clinical data for ISR atherectomy and that can also support lead extraction procedures (the removal of pacemaker or defibrillator leads around the heart).


An innovative cardiology experience with Philips at TCT 2021

Visitors to TCT 2021 will have access to Philips’ latest solutions, plus opportunities to engage with clinical experts and experience innovative cardiac solutions. Philips’ technology advancements in diagnostic, interventional and monitoring solutions at TCT 2021 include:

 

New real-time Philips 3D Intracardiac Echocardiography Catheter — VeriSight Pro: The new VeriSightPro used with Philips’ EPIQ CVx and CVxi Premium Ultrasound Systems offers superior 2D and 3D live image guidance for a wide range of procedures in structural heart disease and electrophysiology.

Advanced ultrasound solutions to set the standard of care for interventional cardiology: Philips Ultrasound System – EPIQ CVxi – is an advanced ultrasound solution that can help clinicians deliver improved care through exceptional image quality, robust quantification, and Echo Navigator live fusion imaging.

Advancing clinical and operational lab performance with Philips Image-Guided Therapy System–Azurion: Intuitive, integrated, and efficient, the next-generation Azurion is an advanced image-guided therapy platform that supports providers to perform procedures easily and confidently with a unique user experience.

Advanced mobile outpatient cardiac monitoring: Philips cardiac care solutions and BioTelemetry’s leading remote cardiac patient monitoring have transformed the cardiac care pathway. This platform integrates data from almost any remote cardiac monitoring device with analysis and support to streamline workflow in clinical practices. 

New clinical data presented at TCT 2021

Five-year outcomes of the iFR-SWEDEHEART trial: On Thursday, Nov. 4, at 1:45 p.m. EST, as part of TCT’s Late-Breaking Clinical Trials and Science program, five-year outcomes of the iFR-SWEDEHEART trial will be presented by Matthias Götberg, M.D., Ph.D., interventional cardiologist and director of the cardiac catheterization lab at Skane University Hospital, Lund, Sweden. Join to hear the data results: iFR-SWEDEHEART: Five-Year Outcomes of a Randomized Trial of iFR-Guided vs. FFR-Guided PC.

 

Large-scale study outcomes on use of IVUS: On Saturday, Nov. 6, at 2:24 p.m. EST, Eric A. Secemsky, M.D., interventional cardiologist at Beth Israel Deaconess Medical Center and assistant professor of medicine at Harvard Medical School in Boston, will present a new large-scale analysis of Centers for Medicare & Medicaid Services (CMS) data on the clinical and economic outcomes of diagnosing and treating peripheral vascular disease using intravascular ultrasound (IVUS). Learn more here about his TCT Innovation Theater session titled: Endovascular Featured Clinical Research – Utilization of Intravascular Ultrasound During Peripheral Venous Intervention Among Medicare Beneficiaries

For more information: www.philips.com/TCT

Related Content

Feature | TCT

November 10, 2021 — There were nine late-breaking trials and 13 late-breaking science presentations at the 2021 ...

Home November 10, 2021
Home
Feature | TCT | Dave Fornell, Editor

Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials ...

Home October 29, 2020
Home
Feature | TCT

October 15, 2020 — The late-breaking studies are one of the hallmarks of the annual Transcatheter Cardiovascular ...

Home October 15, 2020
Home
News | TCT

October 14, 2020 — The American College of Cardiology (ACC) and the Cardiovascular Research Foundation (CRF) are ...

Home October 14, 2020
Home
Videos | TCT

With COVID-19 forcing all medical conferences to go virtual in 2020, Juan F. Granada, M.D., CEO of the Cardiovascular ...

Home August 01, 2020
Home
Feature | TCT | Dave Fornell, Editor

The latest in interventional cardiology clinical data and new device technologies were highlighted at the annual ...

Home November 04, 2019
Home
Feature | TCT

October 10, 2019 — Here are the Cardiovascular Research Foundation (CRF) 12 late-breaking trials and 16 late-breaking ...

Home October 11, 2019
Home
Videos | TCT

Chandan Devireddy, M.D., offers insights about what he saw as the top take aways from the 2019 Transcatheter ...

Home October 04, 2019
Home
Videos | TCT

DAIC Editor Dave Fornell takes a tour of some of the most innovative new cardiovascular technology he found on the expo ...

Home October 03, 2018
Home
Feature | TCT

October 4, 2018 – The Cardiovascular Research Foundation (CRF) had 15 late-breaking trials and 12 late-breaking clinical ...

Home September 21, 2018
Home
Subscribe Now